Marker Therapeutics recently shared an update on the Phase 1 APOLLO study that focused on MT-601, a Multi-Antigen Recognizing (MAR)-T cell product, for patients with lymphoma who have relapsed post anti-CD19 CAR-T cell therapy or cannot undergo such treatment. The company restructured its clinical programs last year, giving priority to MT-601, which has now led to a decrease in Marker Therapeutics’ stock value due to negative sentiment.
The update included safety and efficacy data from the dose escalation segment of the study, indicating a positive safety profile across all doses evaluated (ranging from 100×106 to 400×106 cells) and a 66% objective response rate in Non-Hodgkin Lymphoma (NHL) patients, with half of them showing a complete response. In total, 24 B-cell lymphoma patients, including NHL and Hodgkin Lymphoma (HL) cases, were treated with MT-601, with promising outcomes reported up to the data cutoff in June 2025.
Among the NHL patients who received varying doses of MT-601 and had undergone multiple lines of therapy, 66% showed objective responses, with a 50% complete response rate, and durable responses were observed in some cases lasting up to 24 months. HL patients, who had received a median of eight prior lines of therapy, showed an objective response rate of 78%, further demonstrating the effectiveness of MT-601 across different histologies. The study found no dose-limiting toxicities at the highest dose level of 400×106 cells, and the infusion of MT-601 was well tolerated overall.
The absence of dose-limiting toxicities and the favorable safety profile of MT-601, coupled with the promising response rates observed in the study participants, highlight the potential of this MAR-T cell product in treating lymphomas. The company plans to provide further updates on the data in the first half of 2026, aiming to build upon the current positive outcomes and expand the understanding of MT-601’s efficacy and safety profile.
Marker Therapeutics’ stock experienced a decline of 14.28% following the update on the lymphoma treatment study results, reflecting the impact of market sentiment on biotech companies based on clinical trial outcomes. Despite the stock drop, the company remains focused on advancing MT-601 and leveraging the data from the APOLLO study to drive further research and development efforts in the field of cell therapy for lymphomas.
Key Takeaways:
– Marker Therapeutics’ update on the APOLLO study of MT-601 for lymphoma treatment showcased positive safety and efficacy data across different dose levels.
– The study demonstrated significant response rates in NHL and HL patients, indicating the potential of MT-601 in treating various forms of B-cell lymphomas.
– The absence of dose-limiting toxicities and the well-tolerated infusion of MT-601 are promising indicators for the future development of this MAR-T cell product.
– Despite the stock decline, Marker Therapeutics remains committed to advancing MT-601 and plans to provide further data updates in 2026 to expand the understanding of its therapeutic potential.
Tags: cell therapy
Read more on benzinga.com